NEW YORK – Cohero Health’s pediatric medication adherence pilot with Mount Sinai Health System is just the most recent of several partnerships for the company, as it continues to experience tremendous growth in the respiratory market.
The pilot with the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai will study pediatric asthma patients using Cohero’s connected devices and game-based mobile app to increase and monitor adherence to medication.
“We’ve achieved dramatic and exciting growth this year,” said Mike Marett, Cohero’s chief commercial officer.
Cohero’s connected health tools include: BreatheSmart, a mobile app that lets patients receive medication reminders, track inhaler use and measure lung function; mSpirometer, a mobile spirometer; HeroTracker, which records inhaler usage; and CoheroConnect, a platform that allows patients and caregivers to examine their respiratory health trends on a personal web dashboard.
The company has also announced a partnership with holistic health platform ImagineCare, and introduced a new metered dose inhaler with device manufacturer Presspart Group—work that is all part of Cohero’s mission to get their products into the hands of patients who need them.
“We definitely value partnerships established,” said Marett, “and we enjoy opportunities to collaborate around improving respiratory care. We’re taking our connected suite of products and applying them to the respiratory community, to disrupt and evolve the market.”
Additionally, in November, Cohero announced the completion of what it believes is the first functional connected metered dose inhaler, called the eMDI, the result of a multi-year development effort between Cohero and Presspart. The device incorporates electronics into a medication inhaler to passively track and communicate medication utilization. It incorporates a sensor to track the date and time when medication is actuated, stores that information into onboard memory, and can share it via Bluetooth.
Marett said the company is “channel agnostic,” and works collaboratively with its partners to improve the quality of life and quality of care of patients with respiratory conditions.
“Ideally we’d be outfitting all respiratory patients with the eMDI or HeroTracker and the mSpirometer,” said Marett, “empowering patients and the stakeholders that care for them with actionable insights—this is the holy grail.”